Multiple signatures of a disease in potential biomarker space: Getting the signatures consensus and identification of novel biomarkers

Table 1 Analysis of occurrence events for genes in the ovarian cancer prognostic gene signature set.

#Number of signatures with gene	*Expected Percentage (100 simulations)	Actual Percentage	Enrichment (actual/expected)	Number of genes from our signature	Genes from our signature
0	80.89	52.78	0.65	19	POLA2, NCAPG2, PLAUR, FZD1, CCT2, DNMT1, PIK3R1, POLR2J, TGFBR2, VCL, NCAPD2, POLR2D, HGF, FGFR1, MIS12, ARPC1B, CD93, CDK4, NCAPH
1	17.14	13.89	0.81	5	MMP13, CBX3, CHEK1, LAMA4, TCP1
2	1.89	19.44	10.29	7	CDC6, CAV2, GNG12, CD44, MCM2, CALD1, CFD
3	0.08	5.56	66.67	2	CCL2, PDGFRA
4	0.00	2.78	Not applicable	1	TUBB
5	0.00	2.78	Not applicable	1	EDNRA
6	0.00	2.78	Not applicable	1	COL3A1

Expected and actual frequency of co-occurrences of 36 genes in our prognostic signature with 60 other reference gene signature subsets. All signatures are ovarian cancer-related.
*The expected percentage from 1000 and 10000 simulations can be found in Additional file 3.

ISSN: 1471-2164